CagriSema (pharma stack)
AKA Cagrilintide + semaglutide
Last reviewed 2026-10-30
Our read Opinion
The stack done properly: one product, Phase 3 trials, regulator review.
Claims made by sellers, clinics and users. Not verified.
More weight loss than semaglutide alone by adding an amylin signal for fullness.
GLP-1 and amylin act on different satiety pathways, so combining them was designed to add up.
Evidence level: Human trials ongoing
Tested as a fixed combination in large Phase 3 trials (REDEFINE); submitted to FDA in Dec 2025.
Investigational; FDA decision expected 2026 (verify).
Also sold pre-mixed as CagriSema →Statuses change; check the linked primary sources.
Included as the benchmark. This is what evidence for a combination looks like.
| Field | Cagrilintide | Semaglutide |
|---|---|---|
| Type | Investigational | FDA Approved |
| Regulatory status | Investigational; not FDA-approved | FDA-approved (Ozempic, Rybelsus, Wegovy) |
| Compounding status | Trial use only | Approved product (not applicable) |
| FDA-approved indications | None | Product-specific: type 2 diabetes; chronic weight management in eligible adults and adolescents; cardiovascular risk reduction in eligible adults; kidney/CV risk reduction in adults with type 2 diabetes and CKD; noncirrhotic MASH with F2-F3 fibrosis in adults (accelerated approval). |
| Categories | Metabolic / GLP-1 | Metabolic / GLP-1 |
| Claimed uses |
|
|
| Mechanism | Long-acting amylin analogue that activates amylin receptors involved in satiety and reduced food intake. | GLP-1 receptor agonist that increases glucose-dependent insulin secretion, reduces glucagon and food intake, and delays gastric emptying. |
| Evidence level | Human trials ongoing | Human RCTs (approved use) |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Steady |
| Routes | — | Injection, Oral |
| WADA | Prohibited | Not prohibited |
| Where it stands (opinion) | Randomized phase 2 evidence supports weight-loss activity, with phase 3 development underway. WADA S0 applies to unapproved pharmacological substances such as cagrilintide. | An established prescription therapy with multiple outcome-based indications. Compounded versions are not FDA-approved or interchangeable with approved products. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 1 |
Reuters
A label expansion is under review based on cardiovascular outcomes data.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.